Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions

Padhani, Anwar R.; Koh, Dow‐Mu; Collins, David J.

doi:10.1148/radiol.11110474

Cited by 298 publications

(252 citation statements)

References 134 publications

Supporting

Mentioning

237

Contrasting

Unclassified

Order By: Relevance

“…2 DW-MRI is the most sensitive sequence for lesion detection in bone marrow 3 and it is also highly sensitive in soft tissues. 3,4 Incidental findings are, therefore, inevitable, and a potential trigger for costly and sometimes invasive investigation and a source of anxiety for patients and clinicians. To date there have been no dedicated studies looking at incidental findings in WB DW-MRI studies in patients with myeloma.…”

mentioning

confidence: 99%

Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma

et al. 2016

View full text Add to dashboard Cite

mentioning

confidence: 99%

Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma

et al. 2016

View full text Add to dashboard Cite

“…Marrow hypercellularity presents as diffuse increases in signal intensity on high b -values (Padhani et al 2011(Padhani et al , 2013. Changes in background bone marrow cellularity can affect the visibility of bone marrow metastases.…”

Section: Benign Hematopoietic Marrow Hyperplasiamentioning

confidence: 99%

“…WB-DWI is an emerging imaging technique because it is sensitive to bone marrow cellular density, the relative proportion of fat and marrow cells, water content, and bone marrow perfusion (Padhani et al 2011(Padhani et al , 2013Dietrich et al 2009 ).…”

Section: Diffusion-weighted Imagingmentioning

confidence: 99%

Female Pelvis: Genital Organs

Forstner

Cunha²

2015

Imaging of Complications and Toxicity Following Tumor Therapy

View full text Add to dashboard Cite

Medical Radiology-Diagnostic Imaging is a unique series that aims to document the most innovative technologies in all fi elds within diagnostic imaging and interventional radiology, thereby informing the physician in practice of the latest advances in diagnostic imaging and percutaneous imageguided minimally invasive procedures. Th e contents are intended to cover all organs, and all modern imaging techniques and image-guided treatment modalities, with special emphasis on applications in clinical practice. Each volume is a comprehensive reference book on a topical theme, and the editors are always experts of high international standing. Contributions are included from both clinicians and researchers, ensuring wide appeal. Medical Radiology -Radiation Oncology is a unique series that aims to document the most innovative technologies in all fi elds within radiology, thereby informing the physician in practice of the latest advances in diagnostic and treatment techniques. Th e contents range from contemporary statements relating to management for various disease sites to explanations of the newest techniques for tumor identifi cation and of mechanisms for the enhancement of radiation eff ects, with the emphasis on maximizing cure and minimizing complications. Each volume is a comprehensive reference book on a topical theme, and the editors are always experts of high international standing. Contributions are included from both clinicians and researchers, ensuring wide appeal. This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. AbstractA precise knowledge of antineoplastic drugs is an indispensable basis for the care of patients with cancer. The mechanisms of action and resistance, cross-resistance patterns, pharmacodynamics and pharmacokinetics, pharmacological interaction, and last but not least potential adverse effects should be part of this knowledge. As contemporary cancer care requires interdisciplinary and multiprofessional structures, the radiologist is an important a...

show abstract

“…However, a single functional parameter is often insufficient to be able to objectively describe tumor behavior. Padhani and colleagues therefore proposed multiparametric imaging for the follow-up of tumors [32,33]. Therefore, for example, information regarding tumor perfusion obtained from contrastenhanced CT scans can be supplemented by information regarding metabolic activity from FDG-PET.…”

Section: Review 469mentioning

confidence: 99%

Radiological Monitoring of the Treatment of Solid Tumors in Practice

Ganten

2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!Purpose: Thanks to advances in cancer therapy, the diagnosis of "incurable cancer" is increasingly able to be changed to a chronic disease that is manageable over long periods, resulting in a change in the clinical management of cancer patients with solid tumors. New parameters are needed to measure the success of targeted therapy in clinical trials. Materials and Methods: Review article on the basis of selective literature research. Results: In order to assess how well solid tumors respond to treatment, size-based criteria called RECIST (Response Evaluation Criteria in Solid tumors) have been defined. These criteria have been validated in large oncology trials and are currently used most frequently. New molecular therapies often do not -or at least do not immediately -reduce the size of a tumor. Therefore, RECIST evaluation should be critically assessed especially in the case of modern therapies. Any additional available tumor biology information should be considered. In radiology new methods and developments of RECIST have been introduced to better assess the success of targeted therapy. Conclusion: Assessment according to RECIST has been proven for the follow-up of classic tumor therapy. For the monitoring of targeted therapies, new parameters are often required. Therefore, some specific tumor-and therapy-adapted criteria have already been defined to better evaluate treatment success in clinical trials. Key points:▶ Follow-up evaluation of treatment is becoming increasingly important in modern oncology.▶ Conventional cytostatic/cytotoxic treatments can be evaluated on the basis of size according to RECIST. ▶ However, approx. 80 % of newly approved oncological agents are based on molecular mechanisms of action.

show abstract

Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions

Cited by 298 publications

References 134 publications

Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma

Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma

Female Pelvis: Genital Organs

Radiological Monitoring of the Treatment of Solid Tumors in Practice

Contact Info

Product

Resources

About